Report results from the dry eye chamber crossover trial
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 8 Jun 2022
- Due
- 30 Sep 2022
- Delivered
- 12 Jul 2022
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“results are expected in the third quarter of 2022.”
What we found
Evidence strength A What the grades mean
Aldeyra reported dry eye chamber crossover trial results on July 12, 2022, within the Q3 2022 deadline, showing positive primary endpoints.
-
A SEC filing with company's original commitment
“Enrollment of the crossover dry eye disease trial is substantially complete, and results are expected in the third quarter of 2022.” ✓ confirmed on the page
-
B Aldeyra Therapeutics Achieves Primary Endpoints in Dry Eye Disease Chamber Crossover Clinical Trial
“Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) on July 12, 2022, announced the achievement of the primary endpoints in a crossover clinical trial of 0.25% reproxalap ophthalmic solution”
Checked 2 Oct 2026.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- 1 versions
-
Version 1 · original · stated 8 Jun 2022
Deadline 30 Sep 2022 (“in the third quarter of 2022”) · wording expected
-
Version 2 · stated 28 Nov 2023
Deadline 30 Jun 2024 (“first half of 2024”) · wording expected
“top-line results are anticipated in the first half of 2024, subject to FDA feedback on the SPA”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Report
- Deliverable
- dry eye chamber crossover trial results
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- Medium
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Aldeyra Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2022-ALDX-003469 · Corrections policy